What Is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a 30–31 residue peptide hormone produced by intestinal L-cells after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying and acts on brain appetite centers — properties that made the GLP-1 receptor agonist (GLP-1 RA) medication class the most consequential pharmaceutical development of the decade. Glucagon like peptide 1 receptor agonist medications such as semaglutide, tirzepatide and liraglutide are FDA-approved medicines; the research-grade peptide versions sold by suppliers like hxnetpeptide.com are chemical reference materials for laboratory study, not medicines, and are supplied strictly for research use only.
The Incretin Family: Compound-by-Compound
| Compound | Receptor Pharmacology | Research Context |
|---|---|---|
| Semaglutide | GLP-1 RA; fatty-acylated analog of GLP-1(7-37) | Active ingredient in approved injectable and oral medicines; widely used as analytical reference in bioanalysis labs |
| Tirzepatide | Dual GIP/GLP-1 receptor co-agonist (39-aa, two non-natural residues) | Approved as a medicine (Zepbound/Mounjaro); research material for receptor-selectivity studies. Tirzepatide vs retatrutide comparisons are core reading in metabolic pharmacology programs |
| Retatrutide | Triple agonist: GIP/GLP-1/glucagon receptors | Still investigational; extensively studied in preclinical models. (Spellings retratutide/retrutide also appear in searches and forums.) |
| Tesamorelin | Growth-hormone-releasing hormone analog | Approved for HIV-associated lipodystrophy; tesamorelin peptide stack combination research (e.g. with ipamorelin) is common in metabolic labs. Oral vs injection delivery comparisons are an active formulation question |
| Cagrilintide | Long-acting amylin analog | Studied alongside GLP-1 RAs for combined appetite pathway modulation |
Common search question: "is tirz the same as tirzepatide?" — yes, "tirz" is community shorthand. And "retatrutide vs tirzepatide difference" in one line: tirzepatide activates two receptors (GIP + GLP-1), retatrutide activates three (adding glucagon), which is why researchers describe retatrutide as the more pharmacologically complex tool compound. Community calculators and "retatrutide calc" sheets exist for translating published preclinical dosing into molar terms — always verify with primary literature.
Research Vocabulary You Will Meet
- Injections and sites: published protocols specify injection-site rotation schemes; for research materials, "semaglutide injection sites" refers to animal-study dosing grids described in methods sections.
- Reconstitution: how to reconstitute 15 mg tirzepatide or 5 mg semaglutide vials depends on the diluent volume chosen — see our reconstitution calculator guide for the arithmetic.
- Compounded versions: news about compounded tirzepatide and "grey market GLP-1" supply is a regulatory story, covered in the industry guide — compounded medicines are legal only under specific FDA conditions.
- Community discussion: peptide forum GLP-1 threads and the meso-rx peptide source discussions are where anecdotal reports circulate; treat them as leads, not evidence.
Safety and Study Design Notes
Preclinical literature reports dose-dependent GI effects for this class; sulfur burps and nausea are widely reported clinical side effects of approved GLP-1 medicines, which is why transport and receptor-selectivity studies continue. For laboratory workers, the practical safety questions are handling-related: are peptides safe to inject applies only to approved medicines, never to research vials; and NAD peptide injection side effect reports circulating online involve unregulated products and are not research data. Bleeding after peptide injection reports in forums likewise describe self-experimentation outside any study protocol — we supply analytical-grade material for in vitro work only.
Related Compounds in Metabolic Research
Beyond the incretins, metabolic and endocrine labs frequently order growth hormone releasing peptide family analogs (ipamorelin, sermorelin, CJC-1295, HGH fragment 176-191 benefits studies), follistatin FST fragment research, 5-amino acid metabolic peptides (referred to in searches as "medi k 8 peptide" or "l peptide" mitochondrial research), and the BPC-157 + TB-500 pairing for tissue-repair studies — see the catalog. "What is YK11 peptide" appears often: YK11 is technically a myostatin-inhibiting steroidal compound studied alongside peptides in muscle-wasting research.
Frequently Asked Questions
Q: Do peptides come in pill form for GLP-1 research?
A: Orally available small-molecule GLP-1 agonists are in clinical development, and an oral semaglutide medicine exists; peptide research materials themselves are injectable/lyophilized only, because oral bioavailability of unprotected peptides is negligible.
Q: What is GLP-3?
A: No such receptor ligand class exists — "glucagon like peptide 3" and "GLP-3rt" are community coinages; the family consists of GLP-1, GLP-2 and GIP.
Q: Retatrutide before and after pictures — evidence?
A: Anecdotal; peer-reviewed retatrutide data exist only from registered clinical trials in obesity and diabetes.
Q: Where can I get GLP-1 reference materials tested?
A: Independent labs such as Janoshik and Finnrick verify identity/purity — see the peptide testing guide.